Application of allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia in the era of targeted therapy

VernacularTitle:靶向治疗时代异基因造血干细胞移植在急性淋巴细胞白血病中的应用
Author: Yingjun CHANG ¹ ; Xiangyu ZHAO
Author Information

1. 北京大学人民医院血液科　北京大学血液病研究所　国家血液系统疾病临床医学研究中心　造血干细胞移植治疗血液病北京市重点实验室，北京　100044
Keywords: Leukemia, lymphocytic, acute; Hematopoietic stem cell transplantation; Chimeric antigen receptor T-cell; Blinatumomab
From: Journal of Leukemia & Lymphoma 2022;31(1):11-15
CountryChina
Language:Chinese
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the main curable therapies for patients with acute lymphoblastic leukemia (ALL). This article discusses the status of allo-HSCT for ALL as well as how to combine targeted therapy with allo-HSCT to improve outcomes of ALL in the era of targeted therapy based on the data obtained from the 63rd American Society of Hematology (ASH) Annual Meeting.